7:36AM Zila Product selected to identify pre-cancer in study of leading cancer treatment chemotherapeutic -Erbitux (ZILA) 1.20 : Co announces it has been selected to identify pre-cancerous lesions in a Phase II study of Cetuximab (Erbitux), a cancer therapeutic for head and neck cancer developed by ImClone Systems (IMCL) and distributed by Bristol-Meyers Squibb (BMY).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.